Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Deloitte
Express Scripts
Johnson and Johnson
McKesson
Medtronic
AstraZeneca
QuintilesIMS
Farmers Insurance

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022396

« Back to Dashboard

NDA 022396 describes DYLOJECT, which is a drug marketed by Javelin Pharms Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DYLOJECT profile page.

The generic ingredient in DYLOJECT is diclofenac sodium. There are forty-seven drug master file entries for this compound. Eighty-nine suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
Summary for 022396
Tradename:DYLOJECT
Applicant:Javelin Pharms Inc
Ingredient:diclofenac sodium
Patents:2
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Dermatological Agents
Ophthalmic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 022396
Suppliers and Packaging for NDA: 022396
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396 NDA Hospira, Inc. 0409-1068 0409-1068-01 25 VIAL in 1 CARTON (0409-1068-01) > 1 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength37.5MG/ML (37.5MG/ML)
Approval Date:Dec 23, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 23, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:➤ SubscribePatent Expiration:Jun 18, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Mar 22, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:MANAGEMENT OF PAIN

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Argus Health
Merck
Fuji
Medtronic
AstraZeneca
Novartis
Teva
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot